PPARGC1A¹¹ PPARGC1A
peroxisome proliferator-activated receptor gamma coactivator 1-alpha — the gene encoding PGC-1alpha, the master regulator of mitochondrial biogenesis sits at the center of how your body builds and maintains its energy-producing machinery. Every time you exercise aerobically, AMPK and calcium signaling activate PGC-1alpha, which then switches on hundreds of genes responsible for creating new mitochondria and optimizing their efficiency. More PGC-1alpha activity means more mitochondria, higher aerobic capacity, and greater metabolic resilience.

The rs12640088 variant is an intronic A-to-C substitution within PPARGC1A on chromosome 4. Unlike the well-studied Gly482Ser missense variant (rs8192678), which directly changes the PGC-1alpha protein sequence, rs12640088 sits in a non-coding intron. Intronic variants can still alter gene function through several mechanisms: modified splicing enhancer sequences, changes to intronic regulatory elements, or effects on mRNA secondary structure — any of which could subtly alter the amount or isoform balance of PGC-1alpha produced.

The Mechanism

The precise molecular mechanism by which rs12640088 affects PPARGC1A function has not been characterized in published functional studies. As an intron variant²² intron variant
a DNA change within a non-coding intervening sequence; can affect splicing, mRNA stability, or expression levels without changing the protein directly, it does not alter the amino acid sequence of PGC-1alpha. However, intronic regulatory variants in transcription factors and coactivators are a well-established class of functional polymorphism — the PPARGC1A promoter and intron 1 region in particular contains multiple regulatory elements that respond to exercise-induced signals including CREB binding sites, MEF2 elements, and histone acetylation marks.

The C allele is the minor allele, present at ~12% globally and ~13% in Europeans, with notably lower frequency in South Asian populations (~6%). Its consistent presence across populations suggests it is not strongly deleterious, but the frequency differential hints at possible population-specific selection pressures related to energy metabolism.

The Evidence

The direct evidence for rs12640088 is limited to three published studies, none of which examined exercise or aerobic fitness directly.

Type 2 diabetes and BMI interaction: The most substantive finding comes from a two-stage GWAS-based study of PPAR and PGC1 gene families³³ a two-stage GWAS-based study of PPAR and PGC1 gene families
Villegas et al. Genetic variation in the PPAR and PGC1 gene families and type 2 diabetes. Ann Hum Genet, 2014 in 6,075 Chinese participants. Among the SNPs tested, rs12640088 was the only one in PPARGC1A to show a statistically significant interaction with BMI in relation to type 2 diabetes risk. The study did not find a main-effect association, but the BMI interaction suggests that the variant's metabolic consequences are amplified or revealed by excess adiposity — consistent with PPARGC1A's known role in coupling energy surplus to mitochondrial adaptation and insulin sensitivity.

Liver disease null findings: Two Moroccan studies found no association between rs12640088 and either hepatitis C virus spontaneous clearance or fibrosis progression⁴⁴ hepatitis C virus spontaneous clearance or fibrosis progression
ElFihry et al. Virol Sin, 2020 or hepatocellular carcinoma susceptibility⁵⁵ hepatocellular carcinoma susceptibility
Tanouti et al. Asian Pac J Cancer Prev, 2023, suggesting the variant does not affect PPARGC1A's role in hepatic inflammation or carcinogenesis in these populations.

Practical Implications

Given that rs12640088 lies in PPARGC1A and shows a BMI-dependent interaction with metabolic risk, the most actionable implication for C allele carriers is maintaining healthy adiposity and supporting mitochondrial function — both of which directly modulate how this locus interacts with metabolic outcomes. The gene context suggests aerobic training and mitochondrial support nutrients remain relevant, though no exercise-specific studies have been performed for this variant.

The AA genotype (no C alleles) represents ~76% of the population and shows no evidence of altered risk. The AC heterozygote (~22%) and CC homozygote (~2%) carry one or two copies of the minor allele, with the rare CC genotype having the strongest potential effect.

Interactions

rs12640088 is located in the same gene as rs8192678 (Gly482Ser), the best-studied PPARGC1A variant. These two SNPs could theoretically compound if both reduce PPARGC1A expression or function — however, no study has examined their combined effect, and they are not in strong linkage disequilibrium given their distinct locations (coding exon vs. intron). The Villegas et al. study found rs12640088 was the only PPARGC1A SNP with a significant BMI interaction, distinct from rs8192678's direct fitness and metabolic associations.

The PTPN22 gene encodes lymphoid tyrosine phosphatase (LYP), a critical negative regulator of T-cell receptor (TCR) signaling. While the well-known R620W coding variant¹¹ R620W coding variant
rs2476601, the strongest non-HLA autoimmune risk allele in Europeans, changes arginine to tryptophan at the protein level is the dominant PTPN22 risk variant in Europeans and absent from Asian populations, rs1310182 represents a distinct intronic variant in a putative transcription factor binding site²² putative transcription factor binding site
Intronic variants overlapping transcription factor binding sites can alter PTPN22 expression levels without changing the protein sequence that modulates PTPN22 expression rather than protein function. This variant fills a mechanistic gap: explaining PTPN22-associated autoimmune risk in populations where R620W is essentially absent.

The Mechanism

Unlike R620W, which alters the phosphatase protein's interaction with CSK kinase, rs1310182 (HGVS: NM_015967.7:c.2054-852T>C) is located deep within an intron, 852 nucleotides before exon 16. Its location within a transcription factor binding site³³ transcription factor binding site
Intronic enhancers and transcription factor binding sites can regulate mRNA production and splicing; rs1310182 overlaps a region also shared with the AP4B1 antisense RNA 1 gene suggests the variant influences PTPN22 transcript levels or splicing rather than amino acid sequence. PTPN22 expression is tightly regulated⁴⁴ tightly regulated
PTPN22 is subject to NFAT-dependent transcriptional induction after TCR stimulation, with 2.1–3.6× more transcript in memory and regulatory T cells versus naive T cells; even modest changes in this regulation can shift the threshold at which T cells activate against self-antigens. The functional consequence — altered immune tolerance — mirrors what is seen with R620W, but through a different molecular route.

PTPN22 is expressed predominantly in lymphoid tissue and acts as a negative regulator of TCR signaling by dephosphorylating LCK, FYN, ZAP70, and ITAMs of the TCRζ/CD3 complex. Changes in PTPN22 expression level rather than function can disrupt the delicate balance between effective immune surveillance and inappropriate self-attack.

The Evidence

Population specificity is the defining characteristic of rs1310182. The R620W variant (rs2476601) is essentially absent from East Asian populations (~1% allele frequency), yet PTPN22 haplotypes still show associations with autoimmune disease in these populations. A Japanese haplotype study⁵⁵ Japanese haplotype study
rs1310182 C allele frequency differed significantly between T1D patients and controls; susceptibility haplotype containing rs1310182 risk allele was enriched in T1D patients while protective haplotype was absent demonstrated that rs1310182 is the primary PTPN22 signal for type 1 diabetes in Japanese patients. A separate Japanese study found rs1310182-containing haplotypes associated with autoimmune thyroid disease⁶⁶ rs1310182-containing haplotypes associated with autoimmune thyroid disease
PTPN22 haplotype distribution significantly differed in AITD patients; involvement of PTPN22 locus rather than rs2476601 in AITD development in Japanese (both Graves' disease and Hashimoto's thyroiditis) independently of the R620W locus.

In an Armenian population study⁷⁷ Armenian population study
96 T1D patients vs 100 controls of Armenian descent; T allele OR 4.82, 95% CI 2.38–9.76; TC heterozygotes OR 2.39, 95% CI 1.35–4.24; CC genotype negatively associated with T1D of 96 T1D patients and 100 controls, rs1310182 showed striking association with T1D. The TT homozygote (AA on plus strand) was the primary risk state while TC heterozygotes (AG on plus strand) were at intermediate risk. The CC genotype (GG on plus strand) was negatively associated with T1D in Armenians — protective in that population context. Additionally, the GG (plus-strand) genotype associated with higher HbA1c⁸⁸ GG (plus-strand) genotype associated with higher HbA1c
HbA1c positively correlated with GG genotype at diagnosis and 12 months post-diagnosis in Armenian T1D patients at T1D diagnosis suggests an influence on metabolic control severity once disease is established.

In Europeans, rs1310182 was associated with RA independent of rs2476601⁹⁹ rs1310182 was associated with RA independent of rs2476601
Two PTPN22 SNPs on a haplotype distinct from the R620W haplotype contribute to RA risk independently in Caucasian populations, implying independent functional contributions at the PTPN22 locus.

However, a 2025 updated meta-analysis¹⁰¹⁰ 2025 updated meta-analysis
842 T1D cases and 801 controls across 6 studies; no significant pooled association for rs1310182 in any genetic model tested of T1D associations found no statistically significant pooled association for rs1310182, driven partly by conflicting directionality across populations: the risk allele in Armenians (A/T coding) is the protective allele in Japanese (where G/C coding is the risk allele). This conflicting directionality across populations argues for population-stratified interpretation rather than a single universal risk model.

Practical Implications

The clinical utility of rs1310182 is most relevant for East Asian individuals, where it captures autoimmune risk that rs2476601 does not. For individuals carrying the G allele (the risk allele in East Asian populations), awareness of elevated T1D and autoimmune thyroid disease risk is warranted — especially when combined with other autoimmune risk factors or family history. The HbA1c association in T1D patients suggests that this variant may also relate to glycemic control once disease is established.

For individuals with European or Armenian ancestry, interpretation is more nuanced due to conflicting allele directions. In those populations, the rs2476601 (R620W) variant remains the primary PTPN22 risk signal.

Interactions

Rs1310182 exists on the same haplotype background as other PTPN22 variants including rs2488457 (-1123G>C promoter), rs2476601 (R620W), and rs3789604. In Asian populations where R620W is absent or rare, rs1310182 acts as the primary PTPN22 risk signal. In European populations, rs1310182 may contribute independent risk¹¹¹¹ independent risk
Two SNPs on rs3811021/rs3789605 haplotype associated with RA independent of R620W beyond what rs2476601 alone captures. Combined haplotype analysis of the PTPN22 locus provides better risk stratification than any single variant alone.

For East Asian individuals, the combination of rs1310182-G with risk haplotypes containing rs2488457-C (the functional promoter variant -1123G>C) likely represents the primary PTPN22 autoimmune haplotype in those populations. These two SNPs capture complementary aspects of PTPN22 regulatory variation.

Under normal circumstances, pregnancy is one of the most vasodilatory states the human body can enter. Cardiac output rises by 40–50%, systemic vascular resistance falls, and blood pressure drops in the first trimester before gradually returning toward pre-pregnancy levels at term. Several molecular systems drive this extraordinary expansion of vascular capacity — and natriuretic peptides are among the most important. Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) all promote vasodilation, suppress the renin-angiotensin-aldosterone system, and facilitate sodium excretion. But a gene variant near NPR3 — the receptor that silently removes all three peptides from circulation — may blunt this protective effect precisely when it is needed most.

The Mechanism

The NPR3 gene¹¹ NPR3 gene
Natriuretic peptide receptor 3, also called NPR-C; located at chromosome 5p13.3; functions as a clearance receptor that binds ANP, BNP, and CNP with high affinity and removes them from circulation via receptor-mediated internalization and degradation encodes the dominant clearance mechanism for all three natriuretic peptides. Unlike NPR1 and NPR2 — which signal through intracellular guanylyl cyclase activity — NPR3 primarily acts as a "molecular sink," binding natriuretic peptides and internalizing them for degradation. When NPR3 is more highly expressed or more active, natriuretic peptides are cleared faster, their circulating half-life shortens, and their vasodilatory effects are attenuated.

The rs13154066 variant lies in a regulatory region approximately 40 kb upstream of the NPR3 transcription start site. Analogous blood pressure-associated NPR3 locus SNPs²² blood pressure-associated NPR3 locus SNPs
As shown for the rs1173771 block — blood pressure-elevating alleles reduce NPR3 mRNA in vascular smooth muscle cells via altered chromatin accessibility (Leach et al., Hum Mol Genet 2017, PMID 29016846) have been shown to modulate NPR3 transcript levels: alleles that increase blood pressure correspond to reduced NPR3 expression in vascular smooth muscle, but this apparently paradoxical finding reflects the complexity of the clearance receptor system — reduced NPR3-mediated clearance increases natriuretic peptide half-life, and its net effect on blood pressure can depend on which target tissue and which natriuretic peptide dominate in a given physiologic context. In pregnancy, the relevant signaling context shifts substantially: CNP acts on uterine smooth muscle and spiral arteries³³ CNP acts on uterine smooth muscle and spiral arteries
CNP stimulates endometrial decidualization, promotes trophoblast invasion, and mediates spiral artery remodeling via NPR2 signaling that is tightly regulated by NPR3-mediated clearance, and impaired CNP signaling is mechanistically linked to defective spiral artery remodeling — a central pathologic feature of preeclampsia.

Direct molecular evidence links NPR3 dysregulation to preeclampsia: one study found that NPR-A was absent and NPR-C was upregulated in maternal vessel endothelium from preeclamptic women⁴⁴ NPR-A was absent and NPR-C was upregulated in maternal vessel endothelium from preeclamptic women
Compared to normotensive pregnancies where NPR-C was undetectable in maternal vessels; n=12 tissue samples (6 preeclamptic, 6 normotensive) (Gu et al., Pregnancy Hypertens 2018, PMID 29523263), suggesting that in preeclampsia the balance tips toward clearance and away from productive natriuretic peptide signaling — precisely the opposite of what is needed for blood pressure control during pregnancy.

The Evidence

The strongest evidence for this SNP comes from a landmark multi-ancestry genome-wide association study of hypertensive disorders of pregnancy⁵⁵ multi-ancestry genome-wide association study of hypertensive disorders of pregnancy
Honigberg et al., Nature Medicine 2023; tested 20,064 preeclampsia cases and 703,117 controls, and 11,027 gestational hypertension cases and 412,788 controls; multi-ancestry discovery and replication cohorts that identified rs13154066 as the lead variant at a new locus (5p13) specifically associated with gestational hypertension. Each additional C allele was associated with an approximately 11% higher odds of gestational hypertension (OR 1.11, p=4.5×10⁻¹⁰). Colocalization analysis and polygenic priority scores in this study independently nominated NPR3 as the most likely causal gene at this locus — not a nearby bystander gene.

The causal direction was confirmed in a two-sample Mendelian randomization⁶⁶ two-sample Mendelian randomization
Harpe et al. Int J Hypertension 2025; used 12 NPR3 SNPs as instruments from female-specific UK Biobank data (n=198,402); outcome from 296,824-person preeclampsia GWAS: genetically proxied reduced NPR3 function was associated with a 54% lower odds of preeclampsia (OR 0.46, 95% CI 0.30–0.69). Because reduced NPR3 function means slower natriuretic peptide clearance and therefore higher circulating ANP/BNP/CNP levels, this finding is consistent with the hypothesis that natriuretic peptide signaling is protective in pregnancy hypertension.

A NPR3 missense variant rs2270915 (N521D) has been separately associated with diastolic dysfunction (OR 1.94, p=0.03) in 1,931 randomly selected adults⁷⁷ diastolic dysfunction (OR 1.94, p=0.03) in 1,931 randomly selected adults
Pereira et al., PLOS ONE 2014; G/G homozygotes showed 43% diastolic dysfunction prevalence vs 28% in A/A+A/G genotypes and with blood pressure in two independent diabetic cohorts⁸⁸ blood pressure in two independent diabetic cohorts
Saulnier et al., Diabetes Care 2011; AA homozygotes had ~2.5 mmHg lower SBP than G carriers and greater reduction with dietary salt restriction. These functional associations reinforce that NPR3 genetic variation has real physiologic consequences for cardiovascular regulation — and by extension, for the cardiovascular demands of pregnancy.

Practical Implications

Carriers of the CC genotype at rs13154066 may have modestly higher NPR3-driven natriuretic peptide clearance, attenuating the vasodilatory protection these peptides normally provide during pregnancy. The variant is common (~60% C allele frequency globally), meaning the vast majority of the population carries at least one C allele — its population impact on gestational hypertension risk is therefore substantial even though the per-person OR of 1.11 is modest.

For carriers of CT or CC genotypes, the actionable focus centers on blood pressure surveillance during pregnancy and awareness of gestational hypertension symptoms. Where natriuretic peptide signaling is relevant to clinical decision-making — such as in interpreting BNP or NT-proBNP levels — this genotype may provide useful context. The variant does not currently trigger changes in standard preeclampsia prevention protocols (low-dose aspirin is recommended based on clinical risk factors), but knowing one's genotype can inform both personal vigilance and conversations with prenatal care providers.

Interactions

PLCE1 rs932764 (phospholipase C epsilon 1): Both NPR3 rs13154066 and PLCE1 rs932764 were identified as independent preeclampsia-associated loci in the same Honigberg 2023 multi-ancestry GWAS, and PLCE1 was additionally identified in the multitrait analysis. NPR3 disrupts natriuretic peptide clearance (a blood pressure and vascular tone pathway), while PLCE1 mutations cause nephrotic syndrome and affect podocyte integrity and glomerular filtration — a second pathway that converges on the proteinuria-hypertension axis central to preeclampsia. Individuals carrying risk alleles at both loci may have dual vulnerability: impaired vasodilatory signaling from the NPR3 side and glomerular dysfunction susceptibility from the PLCE1 side, representing two independent pathophysiologic routes to the same clinical syndrome. Proposed compound action: rs13154066 CC + rs932764 risk genotype — "Dual Preeclampsia Risk: NPR3-Mediated Vascular and PLCE1-Mediated Renal Vulnerability." Action type: monitoring. Evidence level: moderate.

NPR3 rs2270915 (N521D missense): This separate NPR3 coding variant is associated with diastolic dysfunction and blood pressure, providing a functional layer of NPR3 impairment that compounds the regulatory effect of rs13154066. Individuals carrying risk alleles at both NPR3 loci (the GWAS regulatory variant and the N521D coding variant) may experience additive impairment of natriuretic peptide clearance efficiency and cardiac pressure-volume regulation. These two variants are in the same gene but appear to operate through distinct mechanisms (regulatory expression vs. protein function), and their combined effect on pregnancy blood pressure has not been formally studied.

The TRAF3IP2 locus on chromosome 6q21 encodes both the Act1 adaptor protein (TRAF3IP2) and an antisense long noncoding RNA (TRAF3IP2-AS1) that acts as a molecular rheostat controlling how much Act1 protein the cell produces. rs13210247 sits inside an intron of TRAF3IP2 but overlaps the TRAF3IP2-AS1 transcript — making it a regulatory variant that fine-tunes the entire IL-17 signaling axis from a position that traditional coding-variant analysis would overlook. The G allele (also designated A4165G in TRAF3IP2-AS1 numbering) was identified as part of the TRAF3IP2 psoriasis susceptibility locus in a landmark 2010 GWAS and has since been shown to carry independent mechanistic weight as a gain-of-function lncRNA variant.

The Mechanism

Act1 is the essential adaptor for IL-17 receptor signaling¹¹ essential adaptor for IL-17 receptor signaling
Act1 couples the cytoplasmic domain of the IL-17RA/IL-17RC receptor complex to TRAF6, driving NF-κB activation and inflammatory gene expression in keratinocytes, fibroblasts, and mucosal epithelium; it is also required for normal keratinocyte differentiation through the AP1 pathway. The gene sits on the minus strand, and overlapping it is TRAF3IP2-AS1, an antisense lncRNA on the plus strand. This lncRNA recruits SRSF10²² SRSF10
Serine/arginine-rich splicing factor 10, a splicing regulator that modulates IRF1 mRNA processing and expression levels when bound to TRAF3IP2-AS1, which then downregulates IRF1 — a transcription factor that drives Act1 expression. More TRAF3IP2-AS1 activity → more SRSF10 recruitment → less IRF1 → less Act1.

The rs13210247 G allele is a gain-of-function mutant³³ rs13210247 G allele is a gain-of-function mutant
In functional assays, the G variant of TRAF3IP2-AS1 shows enhanced ability to recruit SRSF10 compared to the A wild-type, amplifying suppression of the IRF1-Act1 transcriptional axis; treatment with the mouse lncRNA homolog or SRSF10 had therapeutic effects in mouse psoriasis and autoimmune encephalomyelitis models. This enhanced SRSF10 binding → reduced IRF1 → reduced Act1 expression.

How does reducing Act1 increase psoriasis risk? Act1 has a dual role in keratinocyte biology⁴⁴ dual role in keratinocyte biology
Act1/TRAF3IP2 silencing decreases early differentiation markers (KRT1, KRT10, DSC1, DSG1) while increasing late differentiation genes (SPRR2, LCE3) characteristic of psoriatic lesions; this occurs through elevated FosB and Fra1 nuclear expression via AP1 binding sites, independently of the IL-17 pathway; the authors note this paradox remains an active area of investigation. Reducing Act1 disrupts the normal keratinocyte differentiation program through AP1 pathway deregulation, producing a psoriasis-like transcriptional signature. Separately, the missense variant rs33980500 on the same haplotype disrupts Act1's TRAF6-binding domain — so two independent mechanisms (reduced Act1 quantity via rs13210247, and altered Act1 quality via rs33980500) converge on the same locus.

The Evidence

Two independent GWAS published simultaneously in Nature Genetics in 2010 established TRAF3IP2 as a major psoriasis susceptibility locus. Ellinghaus et al.⁵⁵ Ellinghaus et al.
6,487 psoriasis cases and 8,037 controls across German, Swedish, and American cohorts; combined P=2.36×10⁻¹⁰ for rs13210247 identified rs13210247 with an odds ratio of 1.69 (95% CI 1.48–1.94) for psoriasis. Huffmeier et al.⁶⁶ Huffmeier et al.
Discovery cohort of 609 German psoriatic arthritis cases + 990 controls, replicated across six European and North American cohorts confirmed rs13210247 in moderate LD (r²=0.63) with the missense variant rs33980500 — but the two SNPs are on partially distinct haplotype blocks separated by ~9.5 kb, meaning they capture overlapping but not identical disease signal.

The haplotype analysis is where rs13210247's contribution becomes clearest. A four-SNP haplotype carrying rs13196377_G + rs13190932_G + rs33980500_T + rs13210247_A carries an OR of 2.7 (P=0.0054) for psoriasis⁷⁷ OR of 2.7 (P=0.0054) for psoriasis
Haplotype analysis in independent psoriasis cohort following initial GWAS; this is the primary risk haplotype at the TRAF3IP2 locus. A second risk haplotype (rs13196377_A + rs13190932_A + rs33980500_T + rs13210247_G) carries OR=1.8 — rs33980500_T is the shared element conferring risk across both haplotypes, while rs13210247 alleles differ between the two, reflecting two distinct haplotype backgrounds at this locus.

Disease associations extend across the IL-17/autoimmune spectrum. In Chinese cohorts, rs13210247 G is strongly associated with Behçet's disease (OR=2.40, P=6.9×10⁻⁸) and Vogt-Koyanagi-Harada syndrome (OR=2.07, P=7.2×10⁻⁶)⁸⁸ rs13210247 G is strongly associated with Behçet's disease (OR=2.40, P=6.9×10⁻⁸) and Vogt-Koyanagi-Harada syndrome (OR=2.07, P=7.2×10⁻⁶)
Study of 610 BD patients, 721 VKH patients, and 1,591 controls; AG genotype frequency 11.6% in BD vs 4.8% in controls; both conditions share Th17/IL-17 pathway dysregulation with psoriasis. In autoimmune thyroid disease, the AG genotype shows significant association with both Graves' disease and Hashimoto's thyroiditis (https://pubmed.ncbi.nlm.nih.gov/40440802/⁹⁹ https://pubmed.ncbi.nlm.nih.gov/40440802/), extending the locus's relevance beyond skin and mucosa to the endocrine-immune interface.

Practical Implications

rs13210247 sits on the highest-risk psoriasis haplotype at the TRAF3IP2 locus. For carriers who also carry rs33980500_T (D10N), the combined haplotype represents the maximum TRAF3IP2 contribution to psoriatic disease risk — both the quantity of Act1 (reduced by the lncRNA variant) and the quality of Act1 signaling (disrupted TRAF6 binding) are simultaneously compromised.

The breadth of autoimmune associations (psoriasis, psoriatic arthritis, Behçet's disease, VKH syndrome, autoimmune thyroid disease) reflects the centrality of IL-17/Act1 signaling across multiple organ systems. G allele carriers should be aware that autoimmune risk is not organ-specific: a personal or family history of any IL-17-driven condition warrants vigilance across this spectrum.

Known psoriasis triggers that activate Th17 pathways deserve attention: streptococcal pharyngitis, skin trauma (Koebner phenomenon), and psoriasis-precipitating medications (beta-blockers, lithium, antimalarials, interferons). The lncRNA therapeutic angle identified by He et al. is scientifically interesting but not yet clinically actionable.

Interactions

rs13210247 is in moderate LD (r²=0.63) with rs33980500 (D10N), but the two variants are distinct — they co-occur on the high-risk haplotype but also segregate independently. rs13210247 operates at the transcriptional level (Act1 quantity via TRAF3IP2-AS1/SRSF10/IRF1), while rs33980500 operates at the protein level (Act1 TRAF6-binding capacity). Together they represent the two main disease-contributing mechanisms at this locus.

rs13196377 and rs13190932 are the other members of the four-SNP haplotype but appear to be tagging variants rather than functional drivers — they do not independently reproduce the functional effects of D10N or rs13210247.

rs12191877 (HLA-C¹⁰¹⁰ rs12191877 (HLA-C
tags HLA-Cw*0602, the dominant psoriasis susceptibility allele affecting T-cell immune tolerance) creates a dual-hit with TRAF3IP2 rs13210247: impaired self-tolerance (HLA) combined with reduced Act1 regulatory capacity. Because HLA-Cw6 is also a major predictor of biologic therapy response, combined carriers face both elevated disease risk and a pharmacogenomically distinct treatment profile.

The chromosome 9p21.3 region is one of the most studied genetic risk loci in human disease, harboring the long non-coding RNA gene CDKN2B-AS1¹¹ long non-coding RNA gene CDKN2B-AS1
Also called ANRIL — antisense noncoding RNA in the INK4 locus. rs1333040 is an intronic variant within this gene that has been independently associated with two major forms of arterial disease: coronary artery disease (CAD) and intracranial aneurysm (IA). The fact that a single locus influences vascular disease across different arterial beds — coronary arteries in the heart and cerebral arteries in the brain — suggests a shared biological mechanism affecting arterial wall integrity and cell proliferation throughout the vascular system.

The Mechanism

CDKN2B-AS1 (ANRIL) is a regulatory RNA that controls expression of neighboring genes²² controls expression of neighboring genes
ANRIL recruits polycomb repressive complexes PRC1 and PRC2 to silence CDKN2A and CDKN2B, including the cell cycle inhibitors CDKN2A (p16) and CDKN2B (p15). The rs1333040-T risk allele is associated with altered ANRIL expression — Cunnington et al. found that 9p21 risk SNPs correlate with up to 2-fold changes in ANRIL transcript levels. This disrupts the normal regulation of vascular smooth muscle cell proliferation and arterial wall remodeling. Reduced expression of p16/p15 allows smooth muscle cells to proliferate more freely, contributing to both atherosclerotic plaque formation (CAD) and the focal arterial wall weakening that predisposes to aneurysm formation.

Critically, rs1333040 is located in a distinct region of the ANRIL gene (between introns 7 and 15) from the more well-known rs1333049 variant, and the two SNPs tag partly different regulatory elements and risk effects. The rs1333040-T risk allele appears particularly relevant to intracranial aneurysm pathophysiology³³ intracranial aneurysm pathophysiology
The T allele region of ANRIL may affect arterial wall matrix metalloproteinase activity and extracellular matrix remodeling, an arterial vulnerability mechanism distinct from atherosclerosis.

The Evidence

The strongest evidence for rs1333040 comes from intracranial aneurysm genetics. Hashikata et al. 2010⁴⁴ Hashikata et al. 2010
Stroke 2010; 96 familial IA subjects and 419 sporadic IA cases vs 408 controls confirmed that the T allele is associated with both familial IA (transmission disequilibrium test, p=0.002) and sporadic IA (OR 1.28; 95% CI 1.04–1.57). A larger analysis by Nakaoka et al. 2010⁵⁵ Nakaoka et al. 2010
Stroke 2010, Japanese population reported a per-allele OR of 1.43 (95% CI 1.24–1.66), with stronger effects at posterior communicating artery aneurysm sites (OR 1.69). A landmark meta-analysis of over 116,000 individuals⁶⁶ meta-analysis of over 116,000 individuals
Alg et al. Neurology 2013; 32,887 IA cases and 83,683 controls across 61 studies confirmed rs1333040 with a pooled OR of 1.24 (95% CI 1.20–1.29), among the most robustly replicated IA associations in the literature.

For coronary artery disease, multiple meta-analyses confirm the rs1333040 association. Hu et al. 2019⁷⁷ Hu et al. 2019
Bioscience Reports; meta-analysis of 19 studies on ANRIL polymorphisms and CAD found significant associations under dominant, recessive, and allelic models (all p<0.0001). Additionally, Fracassi et al. 2019⁸⁸ Fracassi et al. 2019
Eur Heart J Acute Cardiovasc Care; 133 STEMI patients found that TT homozygotes had significantly higher rates of coronary microvascular obstruction after myocardial infarction (p=0.03–0.04), a complication linked to worse outcomes.

Smoking substantially amplifies the 9p21 risk. Deka et al. 2010⁹⁹ Deka et al. 2010
Stroke; familial IA cohort demonstrated a multiplicative relationship between rs1333040 risk alleles and smoking for intracranial aneurysm risk — carriers who smoke face compounded vascular risk beyond either factor alone.

Practical Actions

The T allele at rs1333040 increases arterial disease risk through mechanisms related to vascular wall integrity and smooth muscle cell regulation. For TT homozygotes, the priority is protecting arterial health from all angles: controlling blood pressure is particularly critical because hypertension is the most potent modifiable risk factor for intracranial aneurysm rupture, and blood pressure control also directly reduces CAD events. Smoking cessation is urgent — the smoking-by-genotype interaction at this locus makes rs1333040 TT one of the clearest examples of gene-environment amplification in vascular disease.

A family history of intracranial aneurysm in first-degree relatives, combined with TT genotype, warrants discussion with a neurologist about screening brain imaging. The 9p21 locus also shows dietary modifiability: the prudent diet pattern (abundant vegetables, fruits, legumes) shown to attenuate 9p21-related CAD risk with sibling variants likely applies across 9p21, though direct diet-interaction studies for rs1333040 specifically are limited.

Interactions

rs1333040 is in partial linkage disequilibrium with other 9p21 variants including rs1333049 (the strongest CAD-associated variant at this locus) and rs4977574 and rs10757278. These variants tag partly distinct functional effects within ANRIL and may compound each other's influence. The rs1333040-T allele is particularly enriched in the intracranial aneurysm risk signature, while rs1333049-C and rs4977574-G are more heavily weighted toward coronary artery disease. Carriers of risk alleles at multiple 9p21 variants face cumulative arterial risk across the vascular system.

The luteinizing hormone/choriogonadotropin receptor (LHCGR) is the primary gateway through which the pituitary communicates its ovulatory signal to the ovary. When the pituitary releases a surge of LH, it binds LHCGR on theca cells and mature granulosa cells, triggering steroidogenesis, follicle rupture, and corpus luteum formation. In males, the same receptor on Leydig cells drives testosterone production. rs13405728 is an intronic variant deep within LHCGR¹¹ intronic variant deep within LHCGR
Located at c.161+4491, meaning 4,491 nucleotides into the first intron of the coding sequence; its exact regulatory effect is still being characterized that was identified as one of the strongest PCOS susceptibility signals in the first genome-wide association study of PCOS — and remains one of the most replicated PCOS loci in Asian populations.

The Mechanism

The A allele at rs13405728 is enriched in PCOS cases and tracks with a hormonal phenotype characterized by elevated androgens, higher LH/FSH ratios, and metabolic dysregulation. Carriers of the AA genotype showed significantly elevated total testosterone, triglycerides, and LDL cholesterol compared to those with the AG or GG genotype²² Carriers of the AA genotype showed significantly elevated total testosterone, triglycerides, and LDL cholesterol compared to those with the AG or GG genotype
Pairwise comparisons in 151 PCOS cases and 99 controls from the Hui Chinese cohort. The protective G allele is present in roughly 7% of Europeans, 27% of East Asians, and 28% of Africans, making this one of the most population-stratified PCOS loci known — a difference that likely explains why PCOS prevalence and phenotype show significant ethnic variation.

The molecular mechanism is not yet established at the protein level, as this is an intronic variant with no direct amino acid consequence. A 2021 three-dimensional genome mapping study identified STON1 and FSHR — not LHCGR itself — as the most likely functional targets of this locus³³ A 2021 three-dimensional genome mapping study identified STON1 and FSHR — not LHCGR itself — as the most likely functional targets of this locus
Hi-C chromatin interaction data showed rs13405728 in spatial contact with STON1 promoter elements and the FSHR regulatory region; LHCGR expression was not differentially expressed in PCOS ovarian tissue despite proximity. STON1 is implicated in adipocyte metabolism; FSHR modulates follicle immune signaling. This finding reframes the locus as a regulatory hub for the broader gonadotropin signaling neighborhood rather than a simple LHCGR coding effect.

The Evidence

The original GWAS by Chen et al.⁴⁴ The original GWAS by Chen et al.
Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nature Genetics, 2011 analyzed three cohorts totalling 4,082 PCOS cases and 6,687 controls from Han Chinese women. rs13405728 emerged as the top hit at the 2p16.3 locus with a combined OR of 0.71 (meaning the G allele is protective) and P=7.55×10⁻²¹ — one of the strongest GWAS signals ever observed for a PCOS locus.

A 2018 meta-analysis pooling 14 case-control studies (11,738 PCOS cases, 35,329 controls)⁵⁵ A 2018 meta-analysis pooling 14 case-control studies (11,738 PCOS cases, 35,329 controls)
Association of luteinizing hormone/choriogonadotropin receptor gene polymorphisms with polycystic ovary syndrome risk. Gynecological Endocrinology, 2018 confirmed the association in Asian populations across multiple genetic models (G vs A: OR=0.735, 95% CI=0.699–0.773; GG vs AA+AG: OR=0.578, P<.001). Importantly, rs13405728 was not significantly associated with PCOS in Caucasian populations — a finding consistent with the low minor allele frequency (~7%) in Europeans, which limits statistical power for detection.

A study of Hui Chinese women found the AA genotype (homozygous risk) present in 65.5% of PCOS cases vs 49.5% of controls⁶⁶ found the AA genotype (homozygous risk) present in 65.5% of PCOS cases vs 49.5% of controls
Association Study between Polycystic Ovarian Syndrome and the Susceptibility Genes Polymorphisms in Hui Chinese Women. PLOS ONE, 2015, with the A allele carrying an OR of 1.729 (95% CI 1.149–2.603) for PCOS diagnosis. The AA genotype specifically showed elevations in total testosterone (69.5 vs 62.2 ng/dL, P=0.014), triglycerides (1.46 vs 1.38 mmol/L, P=0.038), and LDL cholesterol (2.71 vs 2.38 mmol/L, P=0.023).

In IVF outcomes, a 2019 case-control study of PCOS patients undergoing IVF-ET⁷⁷ a 2019 case-control study of PCOS patients undergoing IVF-ET
Association of Rs13405728, Rs12478601, and Rs2479106 SNPs and in vitro fertilization and embryo transfer efficacy in patients with polycystic ovarian syndrome. Medicine, 2019 found that the TT genotype (equivalent to AA on the plus strand) was associated with poor treatment outcomes, including lower clinical gestation rates compared to CT/CC carriers.

The rs13405728 locus also extends beyond reproductive conditions. A study of Han Chinese women⁸⁸ A study of Han Chinese women
Variants in DENND1A and LHCGR are associated with endometrioid adenocarcinoma. Gynecologic Oncology, 2012 found that allele A conferred risk for endometrioid adenocarcinoma (endometrial cancer), connecting the PCOS androgen-signaling pathway to endometrial cancer susceptibility — a link consistent with the established epidemiological association between PCOS and endometrial cancer risk.

Practical Implications

For women carrying the AA genotype, the actionable considerations center on early clinical evaluation for PCOS features, monitoring of androgens and metabolic markers, and awareness of IVF implications. The A allele is the ancestral common allele in all populations — the AA genotype represents the absence of the protective G allele rather than a rare mutation. This contextualizes the risk appropriately: this genotype does not guarantee PCOS, but confers a meaningful increase in susceptibility, especially in East Asian and South Asian individuals where the G allele is substantially more common (27%) than in Europeans (7%).

For individuals of East Asian ancestry, where the G allele frequency (~27%) means the AG genotype is relatively common, heterozygosity provides partial protection worth knowing about. In European individuals, the AG genotype is uncommon enough (~13%) that finding it represents a genuinely meaningful deviation from the background risk.

Interactions

DENND1A rs2479106: The most clinically important compound interaction with this SNP. DENND1A encodes a regulator of androgen biosynthesis in theca cells, and rs2479106 is the other major PCOS GWAS locus. Both were identified in the same original GWAS⁹⁹ Both were identified in the same original GWAS
Chen et al. 2011, Nature Genetics and the same IVF study found that both the AA genotype at rs13405728 AND the AG/GG genotype at rs2479106 independently predicted poor IVF-ET outcomes. When both risk genotypes are present, two distinct PCOS-promoting pathways converge: DENND1A rs2479106 drives abnormal androgen production in theca cells via the DENND1A-CYP17A1 axis, while the rs13405728 locus affects gonadotropin receptor signaling and LH sensitivity. A person carrying both risk genotypes faces a dual-pathway androgen excess phenotype — one from dysregulated biosynthesis, one from altered receptor signaling — which may produce a more severe or treatment-resistant PCOS presentation than either variant alone. The recommended approach for this combination would integrate both biosynthetic pathway support (inositol supplementation targeting DENND1A-linked insulin-androgen coupling) and gonadotropin monitoring (LH/FSH ratio tracking relevant to the LHCGR locus).

LHCGR rs2293275 (N312S): This coding-variant in the same gene (LHCGR Asn312Ser) has documented effects on IVF outcomes and ovarian stimulation response. Carrying both an intronic susceptibility variant (rs13405728) and the coding N312S variant may compound LH receptor signaling alterations, though direct interaction studies between these two specific LHCGR variants are not yet published.

FSHR rs6166 (N680S): The FSH receptor N680S variant governs ovarian response to FSH stimulation and is on the same chromosome (2p) near the LHCGR locus. Both LHCGR and FSHR variants operate in the same gonadotropin signaling neighborhood; combined receptor sensitivity profiles from both genes may define distinct IVF pharmacogenetic subgroups.

NTRK2 encodes TrkB (tropomyosin receptor kinase B), the primary receptor for brain-derived neurotrophic factor (BDNF)¹¹ brain-derived neurotrophic factor (BDNF)
A protein that promotes neuronal survival, growth, and synaptic plasticity — often called the brain's "fertilizer" because of its role in keeping neurons healthy and connected. When BDNF binds TrkB, it triggers intracellular signaling cascades that determine whether neurons form new connections, survive cellular stress, or respond to antidepressants. NTRK2 is consistently implicated in depression genetics — not just as a risk gene, but as a mechanistic hub that explains why some people respond to certain treatments and others don't.

The rs1387923 variant sits in the 3' untranslated region (3' UTR) of the NTRK2 gene — a region that controls mRNA stability and translation efficiency²² mRNA stability and translation efficiency
The 3' UTR contains binding sites for microRNAs and RNA-binding proteins that regulate how much TrkB protein gets made from each mRNA copy. Rather than changing the TrkB protein structure, this variant likely alters how much receptor is produced in neurons, particularly during stress or when antidepressants engage the BDNF pathway.

The Mechanism

TrkB receptor density matters. When BDNF is released from active neurons, it needs sufficient TrkB on the target cell surface to trigger synaptic plasticity³³ synaptic plasticity
The ability of synapses to strengthen or weaken over time, which underlies learning, memory, and mood regulation. A 3' UTR variant affecting mRNA stability could reduce TrkB surface expression in a dose-dependent manner — so G-allele homozygotes may have chronically lower TrkB availability. This would blunt the neurotrophic response to BDNF, impair hippocampal neurogenesis (which is disrupted in depression), and reduce the brain's ability to reorganize after stress.

Critically, many antidepressants — including SSRIs, SNRIs, ketamine, and even lithium — exert part of their effect by upregulating BDNF and potentiating TrkB signaling⁴⁴ upregulating BDNF and potentiating TrkB signaling
These drugs don't just adjust neurotransmitter levels; growing evidence shows they directly enhance TrkB sensitivity and downstream plasticity signaling. A variant reducing TrkB expression may therefore blunt the response to these treatments — a mechanistic basis for treatment resistance.

The Evidence

The strongest evidence for rs1387923 comes from a multicenter prospective study of Han Chinese patients with major depressive disorder⁵⁵ multicenter prospective study of Han Chinese patients with major depressive disorder
Li et al. Journal of Psychiatric Research, 2013, n=948 MDD patients followed longitudinally. Investigators found that the rs1387923+rs1565445 two-SNP haplotype conferred a 1.41-fold increased risk of treatment-resistant depression (p = 0.0014). When BDNF rs6265 was added to form a four-locus model, gene-gene interaction was the strongest predictor of treatment resistance in the entire cohort.

In bipolar disorder, a 2007 pharmacogenetics study⁶⁶ 2007 pharmacogenetics study
Bremer et al. Molecular Diagnostics and Therapeutics, n=184 lithium responders vs. non-responders found significant interactions between rs1387923, rs1565445, and lithium response, particularly when combined with suicidal ideation as a comorbidity. The same NTRK2 variants also appeared in a 2013 bipolar I study⁷⁷ 2013 bipolar I study
Wang et al. Journal of Molecular Neuroscience, n=579 examining mood stabilizer (lithium and valproate) response.

A 2020 Polish case-control study⁸⁸ 2020 Polish case-control study
Suchanek-Raif et al. Disease Markers, n=192 schizophrenia patients, 264 controls found that the G/G genotype at rs1387923 was specifically associated with increased schizophrenia risk in men, while A/A homozygosity was protective. This sex-specific pattern highlights that TrkB signaling interacts with sex hormones in determining psychiatric vulnerability.

A pathway-level perspective comes from a UK population-based imaging study⁹⁹ UK population-based imaging study
Juhasz et al. Biological Psychiatry, 2011, n>2,000 examining nine variants across the CREB1-BDNF-NTRK2 signaling axis. NTRK2 variants amplified the effect of childhood adversity on lifetime depression risk, consistent with the gene's role as a plasticity gate: in people with adequate TrkB signaling, early-life stress may be buffered; with reduced TrkB function, the same stress produces lasting neurobiological changes.

Practical Actions

For those carrying the G allele — particularly G/G homozygotes — the actionable insight is that your BDNF pathway may have a reduced amplification gain, meaning both therapeutic interventions and lifestyle factors that work through BDNF are especially important to maximize. Aerobic exercise is the most consistently effective strategy for increasing both BDNF secretion and TrkB expression in humans, with neuroimaging studies showing hippocampal volume increases that parallel BDNF upregulation. For those who haven't responded to first-line antidepressants, the evidence linking this variant to treatment-resistant depression supports proactive escalation to augmentation strategies — particularly lithium augmentation, where NTRK2 genotype has shown predictive value in pharmacogenetic studies.

Ketamine and ketamine-based treatments (esketamine) work through rapid BDNF/TrkB pathway activation and represent a mechanistically rational escalation option for G/G carriers with treatment-resistant depression.

Interactions

The most important interaction is with BDNF rs6265 (Val66Met). Studies consistently find that rs1387923 risk genotypes combine with BDNF rs6265 to produce gene-gene interactions stronger than either variant alone. In the Li et al. 2013 cohort, the four-locus model (rs1387923 + rs1565445 + rs2769605 + BDNF rs6265) was the key predictor of treatment-resistant depression — suggesting the entire BDNF→TrkB signaling axis needs to be considered together.

The rs1565445 variant is in linkage disequilibrium with rs1387923 and is typically analyzed as part of the same haplotype block. Carriers who also carry rs2769605 represent a higher-risk subgroup with compounded NTRK2 signaling reduction.

Urinary tract infections (UTIs) are among the most common bacterial infections in humans, affecting roughly 50% of women at least once in their lifetime and frequently recurring in a subset genetically predisposed to mucosal colonization by uropathogenic E. coli. While immune signaling genes like TLR4 have long been linked to UTI susceptibility, a 2017 genome-wide association study identified a second independent locus — an intronic variant in FRMD5¹¹ FRMD5
FERM domain-containing protein 5, a cytoskeletal scaffolding protein expressed at epithelial cell junctions — pointing to uroepithelial barrier integrity as a distinct axis of innate UTI defense.

The Mechanism

FRMD5 is a member of the FERM (Four-point-one, Ezrin, Radixin, Moesin) domain superfamily — a class of proteins that physically link the actin cytoskeleton to transmembrane adhesion molecules and junction complexes. FRMD5 localizes to cell adherens junctions and interacts with p120-catenin²² FRMD5 localizes to cell adherens junctions and interacts with p120-catenin
p120-catenin is a key regulator of E-cadherin stability and epithelial barrier function at cell-cell contacts. It also binds directly to the cytoplasmic tail of integrin β5 and inhibits ROCK1-mediated myosin phosphorylation³³ binds directly to the cytoplasmic tail of integrin β5 and inhibits ROCK1-mediated myosin phosphorylation
ROCK1 drives stress fiber contraction; FRMD5 acts as a brake on this pathway to stabilize cell-matrix adhesion, promoting tight cell-surface attachment over migratory, loosely adherent states.

The rs146906133 variant is intronic and does not alter the FRMD5 protein sequence. It likely acts as a regulatory variant affecting FRMD5 transcription or splicing in uroepithelial tissue, although the exact mechanism has not yet been functionally characterized. The plausible biological model is that altered FRMD5 expression changes the structural stiffness of the uroepithelial cell layer — either making it more or less permeable to bacterial attachment and the cytoskeletal remodeling that uropathogenic E. coli exploit during invasion. The rare C allele may increase FRMD5 expression in bladder epithelium, reinforcing tight junction stability and reducing the cytoskeletal rearrangements that allow bacteria to access and persist within uroepithelial cells.

FRMD5 has also been identified as upregulated during Plasmodium berghei infection⁴⁴ upregulated during Plasmodium berghei infection
a rodent malaria parasite, in a serum proteomics study, consistent with the idea that FRMD5 participates in the cell-to-cell adhesion dynamics exploited by intracellular and epithelium-invading pathogens more broadly.

The Evidence

The association at rs146906133 was discovered by Tian et al. in a 2017 Nature Communications genome-wide study⁵⁵ Tian et al. in a 2017 Nature Communications genome-wide study
23andMe research group, analyzing 23 infection phenotypes in over 200,000 individuals of European ancestry. The study identified 59 genome-wide significant associations across all infections, of which the FRMD5 locus was the second independent hit for UTI frequency (the first being a locus near the TLR4 pathway). The T allele (reference, common in >98% of Europeans) was associated with higher self-reported UTI frequency (beta = 0.38, 95% CI 0.32–0.45, p = 2.02×10⁻⁸). Importantly, this study used UTI frequency as a quantitative phenotype, so the beta represents the change in standardized UTI frequency score per allele copy.

The evidence level is emerging: the GWAS signal is genome-wide significant, but the study was observational and self-reported, functional validation of the FRMD5 intronic variant in uroepithelial cells has not been published, and no independent replication cohort has been reported specifically for rs146906133. The biological plausibility is high given FRMD5's established roles in epithelial adhesion, but the mechanistic link to UTI remains inferred.

The C allele is notably more common in East Asian populations (~5.8% allele frequency) than in Europeans (~0.75%) or Africans (<0.1%). Whether the C allele confers the same magnitude of protection in non-European populations has not been tested.

Practical Implications

For the rare carriers of the protective C allele (approximately 1.5% of Europeans carry at least one copy), the genetic data suggest a meaningfully lower biological susceptibility to recurrent UTIs — not immunity, but a measurable difference in how readily uropathogenic bacteria establish persistent mucosal infection. This likely reflects more resilient uroepithelial barrier function rather than any difference in classical immune signaling.

Given that the mechanism involves epithelial structural integrity, factors that further support mucosal barrier health — particularly adequate hydration to maintain urinary flow, and probiotic approaches that compete with uropathogenic colonizers at the vaginal and periurethral mucosa — may complement the genetic protection.

Conversely, the TT genotype (the common reference state) simply reflects the normal population-level baseline susceptibility to UTIs. This genotype alone does not predict recurrent UTIs — many other genetic and behavioral factors (sexual activity frequency, contraceptive choice, anatomical features, other UTI-susceptibility variants) shape overall UTI burden.

Interactions

The FRMD5 locus (rs146906133) and the TLR4 signaling locus represent two independent genetic axes of UTI susceptibility: barrier integrity versus innate immune signaling, respectively. Variants in TLR4 (rs4986790, rs4986791), the secretor status gene FUT2 (which governs whether uropathogens can adhere to certain blood group antigen substrates on the uroepithelium), and complement system genes are all relevant to overall UTI susceptibility and represent distinct pathways from FRMD5's cell adhesion role.

Your kidneys perform a quiet daily miracle: filtering 7–8 grams of uric acid from your blood, then reabsorbing roughly 90% of it back before it can reach the urine. The protein that does most of this recapture is URAT1 (Urate Transporter 1)¹¹ URAT1 (Urate Transporter 1)
Encoded by SLC22A12. An antiporter on the apical membrane of proximal tubule cells that exchanges urate for organic anions (lactate, nicotinate, pyrazinoate), rescuing filtered uric acid back into the bloodstream. Without URAT1, most uric acid would simply spill into the urine. The R90H variant (rs147647315) introduces a histidine at position 90 of the URAT1 protein in place of the usual arginine, destabilising the transporter and impairing its urate-reabsorption function. The result is persistently low serum uric acid — a condition called renal hypouricemia²² renal hypouricemia
A phenotype defined by serum uric acid below 2 mg/dL caused by impaired renal reabsorption; most carriers are asymptomatic but can develop exercise-induced acute kidney injury during vigorous or prolonged physical activity type 1 (RHUC1).

Unlike the more studied W258X variant (rs121907892) that predominates in East Asian populations, R90H (rs147647315) is the primary SLC22A12 loss-of-function allele in populations of African ancestry. A genome-wide association study³³ genome-wide association study
Chen G et al. Refining genome-wide associated loci for serum uric acid in individuals with African ancestry. Hum Mol Genet, 2020 in more than 9,000 continental Africans and African Americans identified rs147647315 as the strongest signal at the SLC22A12 locus (P = 6.65 × 10⁻²⁵) and the sole causal variant at that locus when functional annotation was applied to kidney tissue.

The Mechanism

The arginine at position 90 normally forms a stable hydrogen bond with glutamine 93, helping to anchor that region of the protein. When histidine replaces arginine, the bond lengthens from 2.3 Å (wild-type) to 3.1 Å — at the edge of the hydrogen-bond distance range. This weakened interaction destabilises the local protein domain and likely impairs the folding or membrane integration of URAT1. Structural modelling⁴⁴ Structural modelling
Zhou Z et al. Renal hypouricemia caused by novel compound heterozygous mutations in the SLC22A12 gene: a case report with literature review. BMC Med Genet, 2018 of compound heterozygous patients carrying R90H alongside another truncating mutation confirmed that the resulting protein is functionally impaired, producing the hallmark biochemical phenotype: dramatically elevated fractional excretion of uric acid and very low serum urate.

The broader class of nonfunctional URAT1 variants — of which R90H is one — produces protein that is not properly membrane-localised. Without stable insertion into the apical tubule membrane, URAT1 cannot exchange urate and the kidney's urate recapture capacity is sharply reduced.

The Evidence

African ancestry GWAS: Chen et al. (2020)⁵⁵ Chen et al. (2020)
Chen G et al. Refining genome-wide associated loci for serum uric acid in individuals with African ancestry. Hum Mol Genet, 2020 is the pivotal study for rs147647315 specifically. Among 9,133 participants of African descent, rs147647315 was identified as both the strongest statistical association at the SLC22A12 locus (P = 6.65 × 10⁻²⁵) and the sole functionally prioritised causal variant at that locus, with kidney tissue identified as the relevant biological context. This work established that the A allele of rs147647315 independently drives the serum uric acid-lowering signal at SLC22A12 in this ancestry group.

Phenotypic characterisation of nonfunctional URAT1: Sakiyama et al. (2016)⁶⁶ Sakiyama et al. (2016)
Sakiyama M et al. The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci Rep, 2016 studied 1,993 gout patients and 2,499 health examinees in Japan. Nonfunctional URAT1 variants (R90H and W258X combined) were absent in every single gout case. Among health examinees, males carrying one nonfunctional allele had serum uric acid 2.19 mg/dL lower than those without; females showed 1.08 mg/dL lower levels. Two nonfunctional alleles reduced urate by 5.42 mg/dL (males) and 3.89 mg/dL (females) — a sex-dependent dosage effect (interaction P = 1.5 × 10⁻¹²).

Toyoda et al. (2021)⁷⁷ Toyoda et al. (2021)
Toyoda Y et al. Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12. Rheumatology (Oxford), 2021 quantified the anti-gout protection at a reciprocal OR of 29.6 (P = 7.66 × 10⁻⁸) across all dysfunctional URAT1 variants combined, confirming that functional loss of URAT1 — regardless of the specific mutation — provides among the strongest single-variant gout protection documented in humans.

Large-scale Japanese epidemiology: Kawamura et al. (2021)⁸⁸ Kawamura et al. (2021)
Kawamura Y et al. A proposal for practical diagnosis of renal hypouricemia. Biomedicines, 2021 studied 30,685 Japanese health examinees and confirmed that nonfunctional URAT1 variants (including R90H) significantly increased fractional excretion of uric acid (P = 1.27 × 10⁻⁴⁶ in males) and decreased serum uric acid (P = 2.47 × 10⁻⁵³ in males). The study proposed that FEUA and SUA biomarkers together can guide clinical suspicion of URAT1 variant burden before genetic testing.

Exercise-induced AKI risk: Among individuals with complete or near-complete URAT1 loss of function (homozygous or compound heterozygous for nonfunctional variants), vigorous physical activity can trigger exercise-induced acute kidney injury (EIAKI)⁹⁹ acute kidney injury (EIAKI)
AKI presenting hours after intense exercise with flank pain, haematuria, and oliguria; believed to result from uric acid surges in the tubular lumen exceeding solubility when renal excretion is maximal and urine is concentrated. Kawamura et al. (2021)¹⁰¹⁰ Kawamura et al. (2021) and multiple case series confirm that homozygous or compound heterozygous URAT1 loss-of-function — including R90H paired with W258X or another nonfunctional allele — accounts for most clinically documented EIAKI.

Practical Actions

For heterozygous carriers (AG), the picture is straightforward: moderately lower serum uric acid and strong protection against gout. No specific intervention is required beyond awareness. Exercise is safe with normal hydration precautions.

For the extremely rare homozygous carrier (AA), or compound heterozygous carriers (one A allele at this locus plus a nonfunctional allele at another URAT1 position), the full loss-of-function phenotype produces clinically significant hypouricemia with EIAKI risk. These individuals should be followed by a nephrologist and should understand the pre-exercise hydration and urinary alkalinisation protocols that reduce tubular urate crystal formation risk.

Interactions

rs121907892 (SLC22A12 W258X): The W258X truncating variant is the most common nonfunctional URAT1 allele in East Asian populations. Compound heterozygosity for R90H and W258X — one copy of each nonfunctional allele — produces the same near-total URAT1 loss-of-function as homozygosity for either variant alone. EIAKI risk is highest in this compound heterozygous state. Reports from Japanese patients include R90H/W258X compound heterozygotes with frank hypouricemia.

rs121907896 (SLC22A12 R90H — Japanese-population allele): A separate rsid (rs121907896) refers to what appears to be the same or an overlapping R90H variant designation found predominantly in East Asian populations in the literature. Population genetics of the SLC22A12 locus differs substantially by ancestry — rs147647315 is the African-enriched GWAS signal, while rs121907896 is the Japan-characterised pathogenic R90H allele. Full haplotype resolution in multi-ancestry datasets has not been published.

rs475688 and rs3825016 (SLC22A12 regulatory and coding variants): These common SLC22A12 variants act in the opposite direction — they increase URAT1 activity and raise serum uric acid. Carriers of the rs147647315 A allele alongside risk alleles at rs475688 or rs3825016 would have competing influences on the URAT1 system; the rare protective allele is expected to dominate at the transporter level, but systemic urate outcomes would depend on other pathway variants (SLC2A9, ABCG2).

The FADS2 gene on chromosome 11 encodes delta-6 desaturase¹¹ delta-6 desaturase
The rate-limiting enzyme that performs the first desaturation step in long-chain PUFA synthesis, converting linoleic acid (LA) to GLA and alpha-linolenic acid (ALA) to stearidonic acid — the upstream gating step before all further elongation and desaturation to EPA, DHA, and arachidonic acid, the rate-limiting enzyme that opens the door to all long-chain polyunsaturated fatty acid synthesis from dietary plant precursors. rs1535 is an intronic FADS2 variant studied in large multi-generational cohorts, and it carries a specific distinction among the FADS2 variants on this platform: it shows consistently stronger associations with PUFA substrate accumulation than the nearby rs174575, and it has been prospectively validated as a pharmacogenomic marker identifying who benefits most from omega-3 supplementation after a heart attack.

The Mechanism

Like rs174575, rs1535 acts through an intronic regulatory mechanism that reduces FADS2 expression and delta-6 desaturase activity. The G allele causes the same fundamental substrate-product inversion seen across the FADS2 locus: precursors linoleic acid (LA) and alpha-linolenic acid (ALA) accumulate while downstream products — gamma-linolenic acid (GLA), arachidonic acid (ARA), EPA, and DHA — are reduced. The effect is additive: each G allele further suppresses delta-6 desaturase function, with GG homozygotes showing the most pronounced phenotype.

The two FADS2 variants rs1535 and rs174575 are in high but incomplete linkage disequilibrium (r² = 0.66, D' = 0.97 in European populations²² r² = 0.66, D' = 0.97 in European populations
Steer et al. Human Molecular Genetics, 2012), meaning they travel together most but not all of the time and can be detected as partially independent signals in large cohorts.

The Evidence

The largest longitudinal evidence comes from the Avon Longitudinal Study of Parents and Children, reported by Steer et al.³³ Steer et al.
Steer CD et al. Polyunsaturated fatty acid levels in blood during pregnancy, at birth and at 7 years: their associations with two common FADS2 polymorphisms. Human Molecular Genetics, 2012 in 4,342 pregnant mothers, 3,343 cord blood samples, and 5,240 children at age 7. Crucially, the authors analyzed both rs1535 and rs174575 in the same sample and found rs1535 had consistently stronger PUFA associations — with approximately 60% larger effect sizes for omega-6 substrates such as linoleic acid. At age 7, the rs1535 G allele showed a negative association with arachidonic acid of β=−0.640 (SE 0.019, p<10⁻⁹) and accounted for approximately 18% of the variance in circulating ARA — a larger explained variance than rs174575 at the same locus.

The clinical implications extend beyond fatty acid levels. The OMEGA-REMODEL randomized trial of high-dose omega-3 fatty acids in 358 post-myocardial infarction patients used rs1535 genotyping as a pharmacogenomic marker. In a post-hoc analysis by Kwong et al.⁴⁴ Kwong et al.
Kwong RY et al. Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarction. PLoS One, 2019 of 312 genotyped patients, GG homozygotes showed dramatically greater benefit from omega-3 supplementation: left ventricular end-systolic volume index improved by −4.4 ml/m² on omega-3 versus +1.2 ml/m² on placebo (p=0.006), an odds ratio of 7.2 for clinically meaningful improvement — compared to an OR of 1.2 in AA carriers. NT-proBNP and galectin-3 (cardiac remodeling biomarkers) were similarly reduced only in GG patients on omega-3.

For lactating mothers, rs1535 has been associated with breast milk PUFA composition in studies of Chinese and Taiwanese women. Ding et al.⁵⁵ Ding et al.
Ding Z et al. Association of polyunsaturated fatty acids in breast milk with fatty acid desaturase gene polymorphisms among Chinese lactating mothers. Prostaglandins Leukot Essent Fatty Acids, 2016 found that minor allele carriers at rs1535 had lower concentrations of GLA and arachidonic acid in breast milk in 209 Chinese women, while Wu et al.⁶⁶ Wu et al.
Wu BH et al. FADS Genetic Variants in Taiwanese Modify Association of DHA Intake and Its Proportions in Human Milk. Nutrients, 2020 demonstrated that accumulated G allele dose at rs1535 was associated with lower breast milk DHA proportions in 164 Taiwanese mothers, with a gene-diet interaction: low-DHA-intake mothers carrying the G allele showed the lowest milk DHA concentrations.

Practical Actions

The core implication of G allele carriage at rs1535 is identical to the broader FADS2 picture: plant-based omega-3 sources (flax, chia, walnuts) supply ALA that cannot efficiently convert to EPA and DHA when delta-6 desaturase is impaired. Preformed EPA and DHA from marine or algae-based sources bypass the blocked first step. The unique addition from rs1535 research is the cardiac intervention signal: GG homozygotes recovering from a myocardial infarction had a 7-fold greater probability of cardiac improvement on high-dose omega-3, which is a level of pharmacogenomic specificity not demonstrated for rs174575 alone.

For lactating mothers with GG genotype, the breast milk DHA deficit creates an additional reason to prioritize preformed DHA supplementation during pregnancy and lactation — not just for their own circulating EPA/DHA status but for the DHA content of milk their infants receive.

Interactions

rs1535 and rs174575 are both intronic FADS2 variants in high LD (r²=0.66) with overlapping but not identical biological signals. Individuals carrying G alleles at both rs1535 and rs174575 have additive impairment of delta-6 desaturase activity. Both variants also interact functionally with the downstream FADS1 delta-5 desaturase variants (rs174547, rs174537): reduced delta-6 output from FADS2 limits the substrate available for FADS1 to act on, compounding the PUFA synthesis deficit when both genes carry risk alleles.